Contrast Sensitivity in Glaucoma

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2009 by University of Erlangen-Nürnberg Medical School.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
University of Erlangen-Nürnberg Medical School
ClinicalTrials.gov Identifier:
NCT00947869
First received: July 27, 2009
Last updated: NA
Last verified: July 2009
History: No changes posted
  Purpose

The primary aim of the Erlangen´s Glaucoma Contrast Sensitivity-Study (EGCS-Study) is the evaluation of the diagnostic and prognostic validity of a diagnostic procedure, measuring contrast sensitivity. No therapeutic studies are performed.


Condition
Primary Open Angle Glaucoma
Secondary Open Angle Glaucoma Due to PEX

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Glaucoma Including Pseudoexfoliation Syndrome (SFB 539)

Resource links provided by NLM:


Further study details as provided by University of Erlangen-Nürnberg Medical School:

Estimated Enrollment: 30
Study Start Date: April 2009
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

primary care clinic

Criteria
  • Patients: Primary open angle glaucoma, secondary open angle glaucoma due to PEX
  • Healthy volunteers (for reliability analysis)

Inclusion Criteria:

  • Age > 18
  • Best corrected visual acuity 0.8 or better
  • European

Exclusion Criteria:

  • eye diseases: Infantile glaucoma, angle glaucoma, secondary open angle glaucoma, wich are not due to PEX, diseases involving retina, condition after ophthalmological operations or trauma, cataract, diseases concerning the refractive system, age-related macular degeneration, diabetic retinopathy, optic neuropathy (MS, neuritis), amblyopia
  • Any neurological diseases
  • Systemic diseases with potentially ocular involvement (e.g., diabetes mellitus)
  • Systemic drugs with potentially ocular involvement
  • ocular drugs
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00947869

Contacts
Contact: Anselm G Juenemann, Prof. anselm.juenemann@uk-erlangen.de

Locations
Germany
University Eye Hospital Recruiting
Erlangen, Bavaria, Germany, 91054
Contact: Hohberger    **49-9131-8534521      
Sponsors and Collaborators
University of Erlangen-Nürnberg
Investigators
Study Chair: Anselm G Juenemann, Prof. University Erlangen-Nuremberg
  More Information

No publications provided

Responsible Party: University Eye Hospital Erlangen, University of Erlangen-Nürnberg
ClinicalTrials.gov Identifier: NCT00947869     History of Changes
Other Study ID Numbers: DFG-SFB539-H
Study First Received: July 27, 2009
Last Updated: July 27, 2009
Health Authority: Germany: Ethics Commission

Additional relevant MeSH terms:
Glaucoma
Glaucoma, Open-Angle
Ocular Hypertension
Eye Diseases

ClinicalTrials.gov processed this record on September 18, 2014